Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
about
Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis.Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.Economic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP).HDL in diabetic nephropathy has less effect in endothelial repairing than diabetes without complications.A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.A systematic literature review of methods of incorporating mortality in cost-effectiveness analyses of lipid-lowering therapies.A simulation model to estimate cost-offsets for a disease-management program for chronic kidney disease.Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.Cardiovascular disease: The price of a QALY--cost-effectiveness of statins in CKD.Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.Meta-analysis of lipid-lowering therapy in maintenance dialysis patients.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
P2860
Q30490270-529DD9B3-3500-469A-A2CF-96F7D9A24535Q35576102-5FAFFADA-E688-4045-8AAC-F3BF8B459EE3Q36013827-008FA400-EC15-44D3-B70D-0187FC5074B2Q36247530-B3A9F2AF-5F87-4776-947D-F50AD00A0D96Q36711180-5753B76E-D65C-41DA-AA0C-3F976FD16FE0Q36796655-8ADA1357-F725-4F06-AB61-291B00E6553BQ38638652-8B76CAE5-D8CE-46CC-B686-8255E232AC05Q38754290-99E1B3DE-4827-46DB-9BF1-0740A2D0BCEBQ39092495-742B2466-657F-42A4-A730-00A48C0CF62DQ39102936-C8F96FC6-B06A-4994-B8F7-79EC83639FE2Q43561708-DEC09E97-E779-439C-87CD-589B0918561FQ47648628-316E7F8F-020B-433B-8EBA-7424CEA7222CQ52653977-EA931765-607D-4C0F-9A44-280AC56F7E75Q54342044-8D9A9787-2AF5-4959-92AE-A208A0752ED8Q55476982-AA82F2A1-91A4-46EB-B153-13EBA9CC7ECFQ59167433-2441DBEE-256E-4859-9DB9-98EB1BFE2A70
P2860
Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Cost-effectiveness of statins ...... tion in chronic kidney disease
@en
type
label
Cost-effectiveness of statins ...... tion in chronic kidney disease
@en
prefLabel
Cost-effectiveness of statins ...... tion in chronic kidney disease
@en
P2093
P2860
P1476
Cost-effectiveness of statins ...... tion in chronic kidney disease
@en
P2093
Alan M Garber
Douglas K Owens
Glenn M Chertow
Kevin F Erickson
Sohan Japa
P2860
P304
P356
10.1016/J.JACC.2012.12.034
P407
P577
2013-03-01T00:00:00Z